Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
CNY 30.06
(0.2%)
CNY 30.06
(0.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.43 Billion CNY | -39.69% |
| 2022 | 2.38 Billion CNY | 14.01% |
| 2021 | 2.08 Billion CNY | 86.14% |
| 2020 | 1.12 Billion CNY | 944.66% |
| 2019 | 107.38 Million CNY | -17.15% |
| 2018 | 129.61 Million CNY | 6.94% |
| 2017 | 121.2 Million CNY | -14.82% |
| 2016 | 142.28 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.22 Billion CNY | -14.85% |
| 2024 Q2 | 1.25 Billion CNY | 2.75% |
| 2024 Q3 | 1.18 Billion CNY | -5.81% |
| 2023 Q1 | 2.27 Billion CNY | -4.38% |
| 2023 FY | 1.43 Billion CNY | -39.69% |
| 2023 Q4 | 1.43 Billion CNY | 15.51% |
| 2023 Q3 | 1.24 Billion CNY | -24.87% |
| 2023 Q2 | 1.65 Billion CNY | -27.33% |
| 2022 Q2 | 2.71 Billion CNY | -1.33% |
| 2022 Q1 | 2.75 Billion CNY | 31.87% |
| 2022 FY | 2.38 Billion CNY | 14.01% |
| 2022 Q4 | 2.38 Billion CNY | 41.02% |
| 2022 Q3 | 1.68 Billion CNY | -37.87% |
| 2021 Q1 | 1.31 Billion CNY | 17.55% |
| 2021 FY | 2.08 Billion CNY | 86.14% |
| 2021 Q2 | 2.4 Billion CNY | 82.59% |
| 2021 Q3 | 1.38 Billion CNY | -42.33% |
| 2021 Q4 | 2.08 Billion CNY | 50.38% |
| 2020 Q4 | 1.12 Billion CNY | 239.79% |
| 2020 FY | 1.12 Billion CNY | 944.66% |
| 2020 Q3 | 330.14 Million CNY | 3.52% |
| 2020 Q2 | 318.92 Million CNY | 25.07% |
| 2020 Q1 | 255 Million CNY | 137.47% |
| 2019 Q3 | 82.96 Million CNY | -25.04% |
| 2019 Q4 | 107.38 Million CNY | 29.44% |
| 2019 Q2 | 110.67 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 FY | 107.38 Million CNY | -17.15% |
| 2018 FY | 129.61 Million CNY | 6.94% |
| 2018 Q4 | 129.61 Million CNY | 0.0% |
| 2017 FY | 121.2 Million CNY | -14.82% |
| 2016 FY | 142.28 Million CNY | 0.0% |